

Financial news for ANTH dated on 2020-03-24: Stocks That Hit 52-Week Highs On Tuesday

Financial news for ANTH dated on 2019-12-13: Stocks That Hit 52-Week Lows On Friday

Financial news for ANTH dated on 2018-06-28: Benzinga's Daily Biotech Pulse: Eli Lilly, Edge Therapeutics, BioXcel Report Positive Trial Results, 4 Stocks Debut

Financial news for ANTH dated on 2018-06-27: Anthera Pharma Reports Withdrawal Of Nasdaq's Hearing Request; Trading In Issue Will Be Suspended On Jun. 28, 2018

Financial news for ANTH dated on 2018-05-25: Benzinga's Daily Biotech Pulse: Biomarin Gets FDA Nod, Amarin Settles with Teva, Merck's Cancer Drug Review Extended

Financial news for ANTH dated on 2018-05-18: Benzinga's Daily Biotech Pulse: AstraZeneca's Q1, Novartis-Amgen Migraine Drug Approved

Financial news for ANTH dated on 2018-05-17: Benzinga's Daily Biotech Pulse: ASCO Abstracts, Fibrocell, Ispen And More

Financial news for ANTH dated on 2018-04-16: UPDATE: Anthera Pharma Says Plans To Eliminate Non-Essential Salaried Positions Between Apr. 15-30; Sees Recording Exit Charges ~\$1.2M Related To Restructuring

Financial news for ANTH dated on 2018-04-16: Anthera Pharma 8-K Shows Board Approved, Commenced Mgmt., Admin. Personnel Reorganization

Financial news for ANTH dated on 2018-03-26: 17 Stocks Moving In Monday's Pre-Market Session

Financial news for ANTH dated on 2018-03-16: The Week Ahead In Biotech: Earnings, PDUFA Dates And More

Financial news for ANTH dated on 2018-03-13: Benzinga Pro's Top 10 Most-Searched Tickers On Tues., Mar. 13

Financial news for ANTH dated on 2018-03-13: 46 Biggest Movers From Yesterday

Financial news for ANTH dated on 2018-03-12: Mid-Afternoon Market Update: BlueLink Surges On Cedar Creek Acquisition; Anthera Pharmaceuticals Shares Plunge

Financial news for ANTH dated on 2018-03-12: 32 Stocks Moving In Monday's Mid-Day Session

Financial news for ANTH dated on 2018-03-12: Mid-Day Market Update: Dow Turns Negative; United Community Bancorp Shares Spike Higher

Financial news for ANTH dated on 2018-03-12: Mid-Morning Market Update: Markets Open Higher; Lumentum To Acquire Oclaro For \$9.99/Share

Financial news for ANTH dated on 2018-03-12: Anthera Pharmaceuticals Shares Down 81.9% Following Announcement That Co. Would Terminate Development Of Sollpura After Phase 3 Study Did Not Achieve Primary Endpoint

Financial news for ANTH dated on 2018-03-12: Anthera Pharma's Phase 3 Study of Sollpura Did Not Achieve its Primary Endpoint, Further Development to be Discontinued

Financial news for ANTH dated on 2018-03-12: Anthera Pharma Halted, News Pending

Financial news for ANTH dated on 2018-03-06: Anthera Pharma S-3 Shows Registration For \$100M Mixed Securities Shelf Offering

Financial news for ANTH dated on 2018-03-05: Anthera Pharmaceuticals Reports Q4 EPS \$(0.73) vs \$(0.66) Est.

Financial news for ANTH dated on 2018-02-22: 41 Biggest Movers From Yesterday

Financial news for ANTH dated on 2018-02-21: Mid-Afternoon Market Update: Hackett Group Rises On Upbeat Earnings; QTS Realty Trust Shares Plunge

Financial news for ANTH dated on 2018-02-21: 34 Stocks Moving In Wednesday's Mid-Day Session

Financial news for ANTH dated on 2018-02-21: Mid-Day Market Update: Dow Gains Over 100 Points; Tile Shop Shares Fall On Earnings Miss

Financial news for ANTH dated on 2018-02-21: Anthera Pharmaceuticals Shares Up 37.3% As Roth Capital Initiated Coverage With Buy Rating And \$10.00 Price Target; BZ NOTE: Price Target Represents Nearly 500% Possible Price Appreciation From Where Stock Closed Tues.

Financial news for ANTH dated on 2018-02-21: Benzinga's Top Upgrades, Downgrades For February 21, 2018

Financial news for ANTH dated on 2018-02-21: Roth Capital Initiates Coverage On Anthera Pharmaceuticals with Buy Rating, Announces \$10.00 Price Target

Financial news for ANTH dated on 2018-02-15: 22 Stocks Moving In Thursday's Pre-Market Session

Financial news for ANTH dated on 2018-02-05: Anthera Concludes Last Patient Visit in the Phase 3 RESULT Clinical Study of Sollpura

Financial news for ANTH dated on 2018-01-22: Anthera Announces a 'Positive' Outcome of Second Interim Futility Analysis in the Phase 3 RESULT Clinical Study of Sollpura: Study On Schedule for Topline Data this Quarter

Financial news for ANTH dated on 2017-12-11: Anthera Pharma Offers Outcome Of Interim Futility Analysis In Phase 3 RESULT Trial Of Sollpura: 'study allows for more frequent and higher dose adjustments based upon clinical signs and symptoms than the previous Phase 3 SOLUTION study'

Financial news for ANTH dated on 2017-11-21: 35 Biggest Movers From Yesterday

Financial news for ANTH dated on 2017-11-20: 32 Stocks Moving In Monday's Mid-Day Session

Financial news for ANTH dated on 2017-11-13: Anthera Pharmaceuticals Files For \$50,073,580M Common Stock Offering

Financial news for ANTH dated on 2017-11-06: Anthera Pharmaceuticals Reports Q3 EPS \$(0.58) vs \$(0.91) Est.

Financial news for ANTH dated on 2017-10-24: 33 Stocks Moving In Tuesday's Mid-Day Session

Financial news for ANTH dated on 2017-10-24: Anthera Pharma Prices ~2.307M Share Offering At \$1.25/Share; Warrants For 3 Added Shares Will Have Exercise Price Of \$1.55/Share

Financial news for ANTH dated on 2017-09-07: Anthera Pharma Reports Surpassed 50% Milestone For Screening Of Patients In RESULT Phase 3 Study Of Sollpura In CF

Financial news for ANTH dated on 2017-08-28: Anthera Reports Top Line Final Data from the Extension Period of the Phase 2 BRIGHT-SC Study

Financial news for ANTH dated on 2017-08-14: Anthera Pharma Reports RESULT Phase 3 Study Of Sollpura Will Be Included In European CF Trial Network

Financial news for ANTH dated on 2017-08-09: Anthera Reports FDA Orphan Drug Designation For Blisibimod For Treatment Of IgA Nephropathy

Financial news for ANTH dated on 2017-08-09: Anthera Pharma Reports Q2 EPS \$0.03 vs \$(2.79) In Same Qtr. Last Year

Financial news for ANTH dated on 2017-07-10: Anthera Pharmaceuticals Reports Phase 3 Sollpura Clinical Study Will Be Included In Cystic Fibrosis Foundation Therapeutics Development Network

Financial news for ANTH dated on 2017-07-06: Anthera Reports Expansion of Screening in European Sites in Phase 3 RESULT Clinical Study of Sollpura, Expects Top Line Data At End of 2017 or Early 2018

Financial news for ANTH dated on 2017-05-15: Anthera Announces 1st Patient Screened In RESULT Pivotal Phase 3 Sollpura Study

Financial news for ANTH dated on 2017-05-10: Anthera Pharmaceuticals Reports Q1 EPS \$(2.03) vs \$(1.39) Est.

Financial news for ANTH dated on 2017-05-01: 15 Biggest Mid-Day Losers For Monday

Financial news for ANTH dated on 2017-04-28: Anthera Pharma Reports 1-for-8 Reverse Stock Split

Financial news for ANTH dated on 2017-03-30: 15 Biggest Mid-Day Gainers For Thursday

Financial news for ANTH dated on 2017-03-30: 20 Stocks Moving In Thursday's Pre-Market Session

Financial news for ANTH dated on 2017-03-29: UPDATE: Anthera Says 'Sollpura was well tolerated throughout the 20-Week Extension Period'

Financial news for ANTH dated on 2017-03-29: Anthera Pharma Reports Results from Extension Period of SOLUTION Study of Sollpura: 'demonstrated comparable maintenance in key measurements of height, weight, and BMI'

Financial news for ANTH dated on 2017-03-20: Anson Funds Management Reports 6.2% Stake In Anthera Pharmaceuticals

Financial news for ANTH dated on 2017-03-15: 13G Filing Shows Sabby Management Reporting 8.06% Stake In Anthera Pharmaceuticals

Financial news for ANTH dated on 2017-03-14: Mid-Afternoon Market Update: Dow Falls 50 Points; Moneygram International Shares Surge

Financial news for ANTH dated on 2017-03-14: 18 Biggest Mid-Day Losers For Tuesday

Financial news for ANTH dated on 2017-03-14: Mid-Day Market Update: Crude Oil Down 1.5%; DragonWave Shares Spike Higher

Financial news for ANTH dated on 2017-03-14: 22 Stocks Moving In Tuesday's Pre-Market Session

Financial news for ANTH dated on 2017-03-14: Anthera Prices Offering of 30M Shares at \$0.50/Share

Financial news for ANTH dated on 2017-03-13: Anthera Pharmaceuticals Reports Proposed Public Offering of Common Stock, Warrants

Financial news for ANTH dated on 2017-02-27: Anthera Pharmaceuticals Reports Q4 EPS \$(0.36) vs \$(0.41) Est.

Financial news for ANTH dated on 2017-02-15: Benzinga's Option Alert Recap From February 15

Financial news for ANTH dated on 2017-02-15: Option Alert: Anthera Pharma Apr \$1 Put; 2000 @Bid @\$0.30

Financial news for ANTH dated on 2016-12-30: 4 Big Biotech Losers Heading Into The New Year

Financial news for ANTH dated on 2016-12-29: Benzinga's Top Upgrades, Downgrades For December 29, 2016

Financial news for ANTH dated on 2016-12-29: Where Does Anthera Go From Here?

Financial news for ANTH dated on 2016-12-29: 5 Biggest Price Target Changes For Thursday

Financial news for ANTH dated on 2016-12-29: Jefferies Downgrades Anthera Pharmaceuticals to Hold

Financial news for ANTH dated on 2016-12-29: Citigroup Downgrades Anthera Pharmaceuticals to Neutral

Financial news for ANTH dated on 2016-12-28: Mid-Afternoon Market Update: Dow Falls Over 100 Points; Kate Spade Gains Amid M&A Speculation

Financial news for ANTH dated on 2016-12-28: Suntrust Downgrades Anthera Pharmaceuticals From Buy To Hold, Reduces PT From \$6 To \$1

Financial news for ANTH dated on 2016-12-28: Technical Alert: Anthera Pharmaceuticals Cut In Half

Financial news for ANTH dated on 2016-12-28: 10 Biggest Mid-Day Losers For Wednesday

Financial news for ANTH dated on 2016-12-28: Mid-Day Market Update: Anthera Pharma Drops On Disappointing Phase 3 Data; Ocera Therapeutics Shares Surge

Financial news for ANTH dated on 2016-12-28: Mid-Morning Market Update: Markets Down; Galena Shares Surge On Regulatory Pathway For Thrombosis Treatment

Financial news for ANTH dated on 2016-12-28: 15 Stocks Moving In Wednesday's Pre-Market Session

Financial news for ANTH dated on 2016-12-28: A Peek Into The Markets: U.S. Stock Futures Up Ahead Of Pending-Home Sales Report

Financial news for ANTH dated on 2016-12-28: 5 Stocks You Should Be Watching Today

Financial news for ANTH dated on 2016-12-27: Anthera Shares Down 65% After Hours At \$0.70/Share

Financial news for ANTH dated on 2016-12-27: Anthera Shares to Resume Trade at 4:35 p.m. EST

Financial news for ANTH dated on 2016-12-27: UPDATE: Anthera Says Sollpura Demonstrates Non-Inferiority In Per Protocol CFA Analysis and CNA Analysis; Will Initiate New Study To Demonstrate Efficacy Addressing Scientific Findings In SOLUTION Study

Financial news for ANTH dated on 2016-12-27: Anthera Announces the Phase 3 SOLUTION Study with Sollpura, Misses Primary Endpoint

Financial news for ANTH dated on 2016-12-27: Anthera Halted News Pending

Financial news for ANTH dated on 2016-12-27: Why The Last Week Of 2016 Could Be Big For Biotech Catalysts

Financial news for ANTH dated on 2016-12-07: Mid-Afternoon Market Update: Dow Surges 250 Points; Oxford Industries Shares Tumble

Financial news for ANTH dated on 2016-12-07: Anthera Soars 30% On Kidney Treatment Data

Financial news for ANTH dated on 2016-12-07: 15 Biggest Mid-Day Gainers For Wednesday

Financial news for ANTH dated on 2016-12-07: Mid-Day Market Update: Dave & Buster's Climbs On Upbeat Results; Sigma Designs Shares Slide

Financial news for ANTH dated on 2016-12-07: Mid-Morning Market Update: Markets Mostly Lower; Korn/Ferry Beats Q2 Expectations

Financial news for ANTH dated on 2016-12-07: 20 Stocks Moving In Wednesday's Pre-Market Session

Financial news for ANTH dated on 2016-12-06: Anthera Reports blisibimod Bright-SC IGA Nephropathy Continues To Demonstrate 48 Week Positive Trend Analysis

Financial news for ANTH dated on 2016-12-01: Watch These 5 Huge Put Purchases In Thursday Trade

Financial news for ANTH dated on 2016-11-30: Option Alert: ANTH Jan17 1.0 Puts: 750 @ ASK \$0.15: 750 traded vs 55 OI: Earnings 3/9 Before Open (est) \$1.52 Ref

Financial news for ANTH dated on 2016-11-18: Anthera Pharmaceuticals Expected to Present Phase 2 "Bright-SC" Study Interim Data At ASN Kidney Week Today

Financial news for ANTH dated on 2016-11-17: 10 Stocks With Lowest Close In Three Weeks

Financial news for ANTH dated on 2016-11-11: President-Elect Trump Says Open to Keeping Parts of Obamacare, Including Protection for Pre-Existing Conditions -DJ

Financial news for ANTH dated on 2016-11-10: Mid-Afternoon Market Update: Dow Jumps Over 250 Points; Novavax Shares Slide

Financial news for ANTH dated on 2016-11-10: 15 Biggest Mid-Day Losers For Thursday

Financial news for ANTH dated on 2016-11-10: 20 Stocks Moving In Thursday's Pre-Market Session

Financial news for ANTH dated on 2016-11-10: Anthera Pharma Falls 39% Premarket to \$1.70 Following Failure of SLE Trial to Meet Primary Endpoint

Financial news for ANTH dated on 2016-11-10: Anthera Pharma Shares Resume Trade, Now Down ~58%

Financial news for ANTH dated on 2016-11-10: Anthera Pharma Shares to Resume Trade at 7:30 a.m. EST

Financial news for ANTH dated on 2016-11-10: Anthera Pharma Reports Blisibimod CHABLIS-SC1 Phase 3 Study Did Not Achieve Primary Endpoint

Financial news for ANTH dated on 2016-11-10: Anthera Shares Halted News Pending

Financial news for ANTH dated on 2016-11-08: 7 Binary Trades For The End Of 2016

Financial news for ANTH dated on 2016-11-04: Anthera Pharmaceuticals Reports Q3 EPS \$(0.61) vs. Est. \$(0.38)

Financial news for ANTH dated on 2016-11-02: Anthera Announces That Data From the Phase 2 BRIGHT-SC Study Has Been Accepted as a Late Breaking Abstract at the ASN Kidney Week 2016 Annual Meeting

Financial news for ANTH dated on 2016-10-24: 18 Stocks Moving In Monday's Pre-Market Session

Financial news for ANTH dated on 2016-10-05: 15 Stocks Moving In Wednesday's Pre-Market Session

Financial news for ANTH dated on 2016-08-23: Traders Passing Around Link Highlighting Phase 4 EASY Trial Enrollment, Indicating Confidence In Phase 3 SOLUTION Trial Data At Year End

Financial news for ANTH dated on 2016-08-16: Anthera Pharmaceuticals Announces Appointment of Dr. William Shanahan Jr. as Chief Medical Officer

Financial news for ANTH dated on 2016-08-16: 12 Biggest Mid-Day Gainers For Tuesday

Financial news for ANTH dated on 2016-08-16: Anthera Pharmaceuticals Announces Positive DSMB Review in Phase 3 SOLUTION Study of Solpura, DSMB Had No Concerns Regarding Safety Of Data To Date

Financial news for ANTH dated on 2016-08-09: Anthera Pharma Reports Q2 EPS \$(0.35) vs \$(0.31) Est.

Financial news for ANTH dated on 2016-07-14: Option Alert: ANTH Aug16 2.5 Puts: 500 @ ASK \$0.15: 500 traded vs 230 OI: Earnings 8/8 \$3.42 Ref

Financial news for ANTH dated on 2016-07-08: Anthera Pharmaceuticals Spikes to High of \$3.86 on Vol

Financial news for ANTH dated on 2016-07-08: Benzinga's Top Initiations

Financial news for ANTH dated on 2016-07-08: HC Wainwright Initiates Coverage on Anthera Pharma with Buy Rating, \$10 Price Target

Financial news for ANTH dated on 2016-06-28: Anthera Provides Clinical Program Updates: "Positive trends from BRIGHT-SC Proof-of-Concept Study - Study to Continue"

Financial news for ANTH dated on 2016-06-28: UPDATE: Anthera Says 'CHABLIS-SC1 results to be reported in the third quarter. Recent DSMB review found no safety issues'

Financial news for ANTH dated on 2016-05-25: Option Alert: ANTH Jun16 5.0 Calls Sweep: 500 @ ASK \$0.20: 1920 traded vs 111 OI: \$3.66 Ref

Financial news for ANTH dated on 2016-05-09: Anthera Pharma Q1 EPS (\$0.29) vs (\$0.28) est, Revenue \$145K

Financial news for ANTH dated on 2016-04-21: Mid-Afternoon Market Update: Dow Falls 100 Points; Sarepta Therapeutics Shares Drop Following Release of FDA Briefing Documents on Eteplirsen

Financial news for ANTH dated on 2016-04-11: Mid-Afternoon Market Update: Crude Oil Up 1.7%; Insys Therapeutics Shares Slide

Financial news for ANTH dated on 2016-03-14: Anthera Pharma Files For Mixed Shelf Offering To To \$100M

Financial news for ANTH dated on 2016-03-07: Anthera Pharma Appoints Dr. James Pennington As Interm CMO

Financial news for ANTH dated on 2016-02-19: Anthera Assumed Buy At Jefferies With \$9 PT

Financial news for ANTH dated on 2016-01-12: Citigroup Says Anthera Pharma Outlook For FY 2016 Is Strong, Sees Current Entry Point As 'highly attractive', Reiterates Buy And \$15 PT

Financial news for ANTH dated on 2016-01-05: Anthera Pharma Names Craig Thompson Pres, COO, Chuck Olson as Chief Technology Officer

Financial news for ANTH dated on 2015-12-17: The Top 20 Wall Street Analysts Of 2015

Financial news for ANTH dated on 2015-12-16: Option Alert: ANTH Jan16 5.0 Calls Sweep: 500 @ ASK \$0.55: 500 traded vs 500 OI: \$4.46 Ref

Financial news for ANTH dated on 2015-11-25: Mid-Day Market Update: HP Slides Following Q4 Results; Deere Shares Surge

Financial news for ANTH dated on 2015-10-02: Anthera Announces Initiation of the SOLUTION Clinical Study of Oral Sollpura(R) (liprotamase) Unit-Matched Therapy of Non-Porcine Origin in People With Cystic Fibrosis

Financial news for ANTH dated on 2015-09-17: In The Sea Of Biotechs, Anthera's Multi-Drug Pipeline Makes It Attractive

Financial news for ANTH dated on 2015-09-17: Mid-Morning Market Update: Markets Mostly Flat; Rite Aid Earnings Miss Views

Financial news for ANTH dated on 2015-09-17: Benzinga's Top Initiations

Financial news for ANTH dated on 2015-09-17: Citigroup Initiates Coverage on Anthera Pharmaceuticals at Buy, Announces \$15.00 PT

Financial news for ANTH dated on 2015-09-14: Monday's After-Hours Movers Led By Aquinox, Gray Television, Anthera & Braskem

Financial news for ANTH dated on 2015-09-14: Anthera Reports Termination of Blisibimod Partnership With Zenyaku

Financial news for ANTH dated on 2015-08-10: Anthera Pharmaceuticals Reports Q2 EPS \$(0.25) vs. Est. \$(0.28)

Financial news for ANTH dated on 2015-07-20: Mid-Morning Market Update: Markets Mostly Flat; Morgan Stanley Beats Q2 Views

Financial news for ANTH dated on 2015-07-14: Mid-Afternoon Market Update: Micron Gains On Rumor Of Tsinghua Bid; Navient Shares Drop

Financial news for ANTH dated on 2015-07-14: Anthera Pharmaceuticals Announces Exercise in Full of Underwriters' Option to Purchase Additional Shares, Can Purchase 500K Additional Shares to 3.833M Offered at \$7.50/Share

Financial news for ANTH dated on 2015-07-09: Mid-Day Market Update: Walgreens Surges On Earnings Beat; Coty Shares Slide

Financial news for ANTH dated on 2015-07-09: Mid-Morning Market Update: Markets Open Higher; PepsiCo Earnings Beat Views

Financial news for ANTH dated on 2015-07-09: Morning Market Losers

Financial news for ANTH dated on 2015-07-09: Anthera Pharma Prices ~3.33M Shares at \$7.50/Share

Financial news for ANTH dated on 2015-07-09: Benzinga's Top #PreMarket Losers

Financial news for ANTH dated on 2015-07-09: 7 Stocks To Watch For July 9, 2015

Financial news for ANTH dated on 2015-07-08: Why Alcoa, WD-40, Alibaba, Herbalife, Anthera Pharma Are Moving After-Hours

Financial news for ANTH dated on 2015-07-08: Anthera Pharmaceuticals Announces Proposed Public Offering of Common Stock

Financial news for ANTH dated on 2015-07-08: Anthera Pharmaceuticals Reports Proposed Public Offering

Financial news for ANTH dated on 2015-06-24: Mid-Afternoon Market Update: Dow Drops Over 150 Points; Nektar Therapeutics Shares Spike Higher

Financial news for ANTH dated on 2015-06-24: Mid-Morning Market Update: Markets Open Lower; Lennar Beats Q2 Estimates

Financial news for ANTH dated on 2015-06-06: MaxLinear, PowerSecure, Alaska Air Lead After-Hours Movers To Close The Week

Financial news for ANTH dated on 2015-06-04: Anthera Pharmaceuticals, Aeropostale, Adobe Lead Thursday's After-Hours Movers

Financial news for ANTH dated on 2015-06-04: Anthera Pharmaceuticals Reports Extra Data on Patient-Reported Outcomes From Phase 2b PEARL-SC Blisibimod Study

Financial news for ANTH dated on 2015-05-29: 2 Micro-Cap Pharma Stocks Worth Watching

Financial news for ANTH dated on 2015-05-13: Benzinga's Top #PreMarket Gainers

Financial news for ANTH dated on 2015-05-12: Morning Market Gainers

Financial news for ANTH dated on 2015-05-12: Benzinga's Top Upgrades

Financial news for ANTH dated on 2015-05-12: Citigroup Upgrades Anthera Pharmaceuticals To Neutral

Financial news for ANTH dated on 2015-05-12: Benzinga's Top #PreMarket Gainers

Financial news for ANTH dated on 2015-05-12: Citigroup Upgrades Anthera Pharmaceuticals to Neutral

Financial news for ANTH dated on 2015-05-11: Anthera Pharmaceuticals Reports Q1 Loss \$0.28 Vs Est Loss \$0.31

Financial news for ANTH dated on 2015-03-30: Books-A-Million, HomeAway, Vaalco Energy Lead Monday's After-Hours Movers

Financial news for ANTH dated on 2015-03-23: Anthera Pharma Announces Completion Of Public Offering Of 5.5M Shares at \$4.50/Share; Gross Proceeds Were ~\$25M

Financial news for ANTH dated on 2015-03-19: Anthera Announces \$3 Million Research Award from Cystic Fibrosis Foundation Therapeutics for Development of Sollpura - a Novel Enzyme Therapy

Financial news for ANTH dated on 2015-03-18: Wednesday's After-Hours Movers: Guess?, NQ Mobile And More

Financial news for ANTH dated on 2015-03-18: Anthera Pharma Announces Pricing Of 5.55M Share Offering At \$4.50/Share

Financial news for ANTH dated on 2015-03-18: Benzinga's Top #PreMarket Losers

Financial news for ANTH dated on 2015-03-17: Tuesday's After-Hours Movers: Oracle, Papa Murphy's And More

Financial news for ANTH dated on 2015-03-17: Anthera Pharma Announces Common Stock Offering; No Terms Disclosed

Financial news for ANTH dated on 2015-03-17: Morning Market Gainers

Financial news for ANTH dated on 2015-03-17: Benzinga's Top #PreMarket Gainers

Financial news for ANTH dated on 2015-03-16: Anthera Pharma Completes Interim Analysis From Phase 3 Trial With Blisibimod For IgA Nephropathy

Financial news for ANTH dated on 2015-03-16: Anthera Pharma Reports Q4 EPS \$(0.32) vs. Est. \$(0.33)

Financial news for ANTH dated on 2015-03-16: Anthera Pharmaceuticals Says On March 12, 2015, Entered Into Purchase Agreement With Lincoln Park Capital Fund; Has Right to Sell Up to \$10 M of Company's Common Stock

Financial news for ANTH dated on 2015-03-10: After-Hours Movers Led By Pioneer Energy, Weibo & Habit Restaurants

Financial news for ANTH dated on 2015-03-09: TheStreetSweeper releases a new investigative report on Anthera Pharmaceuticals

Financial news for ANTH dated on 2015-02-10: Anthera Pharmaceuticals Regains Listing Requirement With Nasdaq

Financial news for ANTH dated on 2015-02-10: Morning Market Gainers

Financial news for ANTH dated on 2015-02-10: Anthera Pharmaceuticals Completes Interim Analysis from Phase 3 Trial with Blisibimod

Financial news for ANTH dated on 2015-02-02: 7 U.S. Health Care Penny Stocks With Upside Potential Greater Than 100%

Financial news for ANTH dated on 2015-01-07: Anthera Pharmaceuticals Appoints Klara Dickinson As SVP, Chief Regulatory Officer

Financial news for ANTH dated on 2014-12-15: Anthera Pharma Reports License of Japanese Rights for Blisibimod to Zenyaku Kogyo, Co. Will Receive Up to \$48M Plus

## Future Product Margin

Financial news for ANTH dated on 2014-11-20: Anthera, Patheon Sign Manufacturing Agreement For Liprotamase Phase III Registration Trial

Financial news for ANTH dated on 2014-10-01: Anthera Pharmaceuticals Announces Update On Strategic Partnership Discussions for Blisibimod

Financial news for ANTH dated on 2014-09-17: Stocks Hitting 52-Week Lows

Financial news for ANTH dated on 2014-07-28: Anthera Pharmaceuticals, Inc. Reports Q2 EPS of \$(0.34) vs \$(0.49) Est

Financial news for ANTH dated on 2014-07-15: Benzinga's Top #PreMarket Gainers

Financial news for ANTH dated on 2014-07-14: Shares of Anthera Pharma to Resume Trade at 5:10 p.m. EDT

Financial news for ANTH dated on 2014-07-14: UPDATE: Anthera Names Chuck Olson as Pres of Alkira, Alkira Will Secure Funding, to Make Milestone, Royalty Payments on Sollpura

Financial news for ANTH dated on 2014-07-14: Anthera Pharmaceuticals Announces Acquisition of Sollpura For Exocrine Pancreatic Insufficiency From Eli Lilly And Company - No Terms

Financial news for ANTH dated on 2014-07-14: Anthera Pharma Shares Halted News Pending

Financial news for ANTH dated on 2014-05-15: Afternoon Market Movers

Financial news for ANTH dated on 2014-05-13: Anthera Pharmaceuticals, Inc. Reports Q1 EPS of \$(0.39) vs \$(0.46) Est

Financial news for ANTH dated on 2014-02-10: Hansen Medical Announces Appointment of Chris Lowe as Interim CEO; Bruce Barclay to Depart the Company

Financial news for ANTH dated on 2013-11-20: Anthera Pharmaceuticals Accused of Withholding Data

Financial news for ANTH dated on 2013-10-29: Anthera Pharmaceuticals, Inc. Reports Q3 EPS of \$(0.30) vs \$(0.61) Est

Financial news for ANTH dated on 2013-07-30: Anthera Pharmaceuticals Reports Q2 EPS of (\$0.43) vs. (\$0.61) Est.

Financial news for ANTH dated on 2013-07-15: Stocks To Watch For July 15, 2013

Financial news for ANTH dated on 2013-07-12: Anthera Pharmaceuticals Announces 1-for-8 Reverse Split of Stock

Financial news for ANTH dated on 2013-06-12: Anthera Pharma CFO to Leave

Financial news for ANTH dated on 2013-05-07: Anthera Pharmaceuticals Announces Additional Data from Phase 2b PEARL-SC Blisibimod Study

Financial news for ANTH dated on 2013-03-28: McNicoll Lewis Vlak Maintains Buy on Anthera Pharmaceuticals, Inc., Lowers PT to \$2.00

Financial news for ANTH dated on 2013-03-26: Anthera Pharmaceuticals, Inc. Reports Q4 EPS of \$(0.11) vs \$(0.16) Est

Financial news for ANTH dated on 2013-03-05: UPDATE: Jefferies Initiates Anthera Pharmaceuticals at Buy on Blisibimod Outlook

Financial news for ANTH dated on 2013-03-05: Jefferies Initiates Coverage on Anthera Pharmaceuticals, Inc. at Buy, Announces \$2.00 PT

Financial news for ANTH dated on 2013-01-28: Anthera Pharma Files Supplement for 60.6M Shares

Financial news for ANTH dated on 2013-01-25: Anthera Pharma Prices 60.6M Shares at \$0.66/Share

Financial news for ANTH dated on 2012-09-17: Benzinga's Microcap Movers for Monday September 17, 2012

Financial news for ANTH dated on 2012-09-17: Anthera Announces the Advancement of Blisibimod into Phase 3 Development



Financial news for ANTH dated on 2012-08-26: Benzinga's Microcap Movers for Friday August 24, 2012

Financial news for ANTH dated on 2012-08-24: Anthera Pharmaceuticals Spokesperson Indicates there is No News Today to Account for Spike in Share Price

Financial news for ANTH dated on 2012-08-24: Anthera Pharmaceuticals Spiking Hugher

Financial news for ANTH dated on 2012-08-07: Anthera Pharmaceuticals Reports Q2 EPS \$-0.43 vs \$-0.32 Est

Financial news for ANTH dated on 2012-07-19: Anthera Pharmaceuticals Announces Pricing of Public Offering of Common Stock; 33M Shares at \$1.00/Share

Financial news for ANTH dated on 2012-07-18: Benzinga's Microcap Movers for Wednesday July 18, 2012

Financial news for ANTH dated on 2012-07-18: Anthera Pharmaceuticals Announces Proposed Public Offering of Common Stock; No Amount Given

Financial news for ANTH dated on 2012-07-17: Benzinga's Microcap Movers for Tuesday July 17, 2012

Financial news for ANTH dated on 2012-07-16: Benzinga's Microcap Movers for Monday July 16, 2012

Financial news for ANTH dated on 2012-07-16: Anthera Pharmaceuticals Provides Additional Data from the Recently Completed PEARL-SC Study of Blisibimod in the Proposed Phase 3 Population

Financial news for ANTH dated on 2012-07-09: Canaccord Maintains Anthera Pharmaceuticals at Buy, Lowers PT from \$6 to \$3

Financial news for ANTH dated on 2012-06-29: Ascendant Capital Markets Downgrades Anthera Pharmaceuticals from Buy to Neutral, Lowers PT from \$2.50 to \$0.90

Financial news for ANTH dated on 2012-06-29: UPDATE: Citigroup Downgrades Anthera Pharmaceuticals to Sell on Modest Efficacy to Drug Phase 2

Financial news for ANTH dated on 2012-06-29: Citigroup Downgrades Anthera Pharmaceuticals from Neutral to Sell, Lowers PT from \$0.50 to \$2

Financial news for ANTH dated on 2012-06-28: Piper Jaffray Maintains Anthera Pharmaceuticals at Overweight, Lowers PT from \$6 to \$2

Financial news for ANTH dated on 2012-06-28: Anthera Pharmaceuticals Down 65% After Reporting Phase 2b PEARL-SC Clinical Study Results

Financial news for ANTH dated on 2012-06-28: Benzinga's Top Downgrades

Financial news for ANTH dated on 2012-06-27: Anthera Updates Phase 3 Plans

Financial news for ANTH dated on 2012-06-16: Benzinga's Microcap Movers for Friday June 15, 2012

Financial news for ANTH dated on 2012-06-13: Four Winning Trades Based on Analyst Ratings

Financial news for ANTH dated on 2012-06-13: JMP Securities Initiates Anthera Pharmaceuticals at Market Outperform

Financial news for ANTH dated on 2012-06-01: Ascendant Capital Markets Initiates Coverage on Anthera Pharmaceuticals at Buy, Announces PT of \$2.50

Financial news for ANTH dated on 2012-05-04: Citigroup Maintains Anthera Pharmaceuticals at Neutral, Lowers PT from \$3 to \$2

Financial news for ANTH dated on 2012-04-25: Anthera Announces the Completion of Patient Dosing in Phase 2b PEARL-SC Study

Financial news for ANTH dated on 2012-03-15: Benzinga's Top Downgrades

Financial news for ANTH dated on 2012-03-15: UPDATE: Auriga Downgrades Anthera Pharmaceuticals

Financial news for ANTH dated on 2012-03-15: Auriga Downgrades Anthera Pharmaceuticals from Hold to Sell, Maintains PT at \$57

Financial news for ANTH dated on 2012-03-12: UPDATE: Wedbush Lowers PT to \$4 on Anthera Pharmaceuticals

Financial news for ANTH dated on 2012-03-12: Morning Market Losers

Financial news for ANTH dated on 2012-03-12: Benzinga's Top Pre-Market Losers

Financial news for ANTH dated on 2012-03-12: Wedbush Securities Maintains Anthera Pharmaceuticals at Outperform, Lowers PT from \$8 to \$4

Financial news for ANTH dated on 2012-03-12: Benzinga's Top Downgrades

Financial news for ANTH dated on 2012-03-12: UPDATE: Anthera Halts VISTA-16 Clinical Study Due to Lack of Efficacy Following Recommendation by the Independent Data Safety Monitoring Board

Financial news for ANTH dated on 2012-03-12: UPDATE: Deutsche Bank Cuts Target on Anthera Pharmaceuticals to \$14

Financial news for ANTH dated on 2012-03-12: UPDATE: Citigroup Downgrades Anthera Pharmaceuticals to Hold

Financial news for ANTH dated on 2012-03-12: Citigroup Downgrades Anthera Pharmaceuticals from Buy to Neutral, Lowers PT from \$11 to \$3

Financial news for ANTH dated on 2012-03-12: Deutsche Bank Maintains Anthera Pharmaceuticals at Buy, Lowers PT from \$14 to \$4

Financial news for ANTH dated on 2012-03-09: Anthera Shares Fall 60% After-Hours on Halt of VISTA-16 Clinical Study

Financial news for ANTH dated on 2012-03-09: Anthera Halts VISTA-16 Clinical Study Due to Lack of Efficacy Following Recommendation by the Independent Data Safety Monitoring Board

Financial news for ANTH dated on 2012-03-05: Anthera Pharmaceuticals Completes Interim Analysis of PEARL-SC Clinical Trial with Blisibimod

Financial news for ANTH dated on 2012-03-02: UPDATE: Summer Street Research Partners Initiates Buy, \$15 PT on Anthera Pharmaceuticals

Financial news for ANTH dated on 2012-03-02: Summer Street Initiates Coverage on Anthera Pharmaceuticals at Buy, Announces PT of \$15

Financial news for ANTH dated on 2012-02-22: Morning Social Media Outlook for Wednesday Feb 22

Financial news for ANTH dated on 2012-02-22: Anthera Pharmaceuticals Reports 2011 Fourth Quarter Financial Results and Provides Clinical Progress Update

Financial news for ANTH dated on 2011-12-14: Anthera Announces Completion of Safety Review by DSMB for VISTA-16

Financial news for ANTH dated on 2011-12-08: UPDATE: Canaccord Initiates Buy, \$13 Target on Anthera Pharmaceuticals

Financial news for ANTH dated on 2011-12-08: Canaccord Initiates Anthera Pharmaceuticals at Buy, \$13 PT

Financial news for ANTH dated on 2011-12-02: UPDATE: Wedbush Upgrades Anthera Pharmaceutical to Outperform

Financial news for ANTH dated on 2011-12-02: UPDATE: Collins Stewart Initiates Coverage on Anthera Pharmaceuticals

Financial news for ANTH dated on 2011-12-02: Benzinga's Top Upgrades

Financial news for ANTH dated on 2011-12-02: Collins Stewart Initiates Anthera Pharmaceuticals at Buy, \$13 PT

Financial news for ANTH dated on 2011-12-02: Wedbush Upgrades Anthera Pharma to Outperform, PT Raised to \$8

Financial news for ANTH dated on 2011-12-01: Citi Maintains Buy Rating and \$11 PT on Anthera Pharmaceuticals

Financial news for ANTH dated on 2011-11-29: Deutsche Bank Maintains Buy Rating and \$14 PT on Anthera Pharmaceuticals

Financial news for ANTH dated on 2011-11-01: Anthera Pharma Reports Reports Q3 EPS \$(0.60) May Not be Comparable to \$(0.55) Est

Financial news for ANTH dated on 2011-11-01: Deutsche Bank Initiating Coverage on Anthera Pharmaceuticals

Financial news for ANTH dated on 2011-11-01: Deutsche Bank Initiates Coverage on ANTH, ARUN

Financial news for ANTH dated on 2011-10-25: Anthera Announces Last Patient Enrolled in PEARL-SC Study

Financial news for ANTH dated on 2011-10-11: Monday's NASDAQ Top Percentage Gainers

Financial news for ANTH dated on 2011-09-19: Citigroup Initiates Anthera Pharmaceuticals at Buy, \$11 PT

Financial news for ANTH dated on 2011-09-08: Anthera Pharmaceuticals Announces Notice of Allowance of U.S. Patent Application Covering A-002 Plus Statin Compositions

Financial news for ANTH dated on 2011-06-23: Anthera Pharmaceuticals Files to Sell 321K Shares

Financial news for ANTH dated on 2011-06-03: Anthera Pharmaceuticals Prices Public Offering of 6.67M Shares at \$7.50 per Share

Financial news for ANTH dated on 2011-06-02: Tonight's Notable Events

Financial news for ANTH dated on 2011-06-02: Anthera Pharmaceuticals Announces Proposed Public Offering of Common Stock

Financial news for ANTH dated on 2011-05-23: UPDATE: Piper Jaffray Raising Price Target On Anthera Pharmaceuticals

Financial news for ANTH dated on 2011-05-23: Piper Jaffray Raises PT On Anthera Pharmaceuticals To \$12

Financial news for ANTH dated on 2011-05-17: Morning NASDAQ Top Percentage Gainers

Financial news for ANTH dated on 2011-05-17: NASDAQ Stocks Hitting 52-Week Highs (LONG, TECH, ANTH, TSTF)

Financial news for ANTH dated on 2011-05-11: Anthera Holder Vantagepoint Cuts Stake to 17.5% from 19.1% -Bloomberg (ANTH)

Financial news for ANTH dated on 2011-04-18: Anthera Pharmaceuticals Successfully Completes Interim Biomarker Analysis of VISTA-16 Study and Third Safety Review of Varespladib Methyl

Financial news for ANTH dated on 2011-03-09: Stocks To Watch When Human Genome Sciences Reopens After Benlysta Approval (HGSI, GSK, LJPC, ANTH, CEPH)

Financial news for ANTH dated on 2011-02-23: Anthera Pharmaceuticals Reports Q4 EPS of \$(0.40) vs. \$(0.31)

Financial news for ANTH dated on 2011-01-11: Anthera Resumes Trial Testing On Lupus Patients While Starting On Other New Trials

Financial news for ANTH dated on 2010-11-17: Piper Jaffray Comments On Anthera's Lupus Trial

Financial news for ANTH dated on 2010-10-04: Piper Jaffray Lowers Price Target On Anthera Pharmaceuticals

Financial news for ANTH dated on 2010-09-23: Anthera Pharmaceuticals Skyrocketing (ANTH)

Financial news for ANTH dated on 2010-09-21: Anthera Pharmaceuticals Announces Pricing of \$31.5 Million Financing

Financial news for ANTH dated on 2010-07-15: Piper Jaffray Reiterates Overweight Rating On Anthera Pharmaceuticals (ANTH)

Financial news for ANTH dated on 2010-04-23: ANTH Opened With Outperform at Cowen